Trial Profile

A Phase 1b Clinical Trial to Evaluate BEBT-908 for Injection in Patients with Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BEBT 908 (Primary) ; Fulvestrant (Primary)
Indications Advanced breast cancer; Carcinoma; Cervical cancer; Colorectal cancer; Head and neck cancer; HER2 negative breast cancer; Liver cancer; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors BeBetter Med

Most Recent Events

03 Apr 2023 New trial record
22 Dec 2021 According to BeBetter Med media release, Guangzhou BeBetter Medicine Technology changed its name to BeBetter Med.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com